摘要
This study provides an overview of the current landscape of biomarkers for colorectal cancer(CRC)detection,focusing on genetic,proteomic,circulating microRNA(miRNA),and metabolomic biomarkers.CRC remains a significant global health challenge,ranking among the most prevalent cancers worldwide and being a leading cause of cancer-related deaths.Despite advancements in screening methods such as colonoscopy,sigmoidoscopy,and fecal occult blood tests(FOBT),the asymptomatic nature of early-stage CRC often results in late diagnoses,negatively impacting patient outcomes.Genetic biomarkers like APC,KRAS,TP53,and microsatellite instability(MSI)play critical roles in CRC pathogenesis and progression.These biomarkers,detectable through polymerase chain reaction,next-generation sequencing,and other advanced techniques,guide early detection and personalized treatment decisions.Proteomic biomarkers such as CEA,CA 19-9,and novel signatures offer insights into CRC’s physiological changes and disease status,aiding prognosis and treatment response assessments through enzyme-linked immunosorbent assay and mass spectrometry.Circulating miRNAs,including miR-21 and miR-92a,present promising non-invasive biomarkers that can be detected in blood and stool samples,reflecting CRC presence,progression,and therapeutic response.Metabolomic biomarkers,encompassing amino acids,lipids,and TCA cycle intermediates,provide further insights into CRC-associated metabolic alterations,which are crucial for early detection and treatment monitoring using mass spectrometry and nuclear magnetic resonance.Despite these advancements,challenges such as biomarker validation,standardization,and clinical utility remain.Future research directions include integrating multi-omics approaches and leveraging technologies like liquid biopsies and AI for enhanced biomarker discovery and clinical application.By addressing these challenges and advancing research in biomarker development,CRC screening and management could potentially be revolutionized,improving patient outcomes and reducing the global burden of this disease.
